Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Multicenter, Double-Blind, Placebo-Controlled Study of LY2140023 in Japanese Patients with Schizophrenia
jRCT2080221118Phase 2
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pomaglumetad methionil in schizophrenia (4 arms), sponsored by Eli Lilly and Company.
02
Drugs
pomaglumetad methionil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2080221118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221118.